Spyglass Pharma, INC Form 4 insider transactions

RA Capital Management and its affiliated funds significantly increased their beneficial ownership in SpyGlass Pharma, Inc. through preferred stock conversion and a substantial common stock purchase at $16 per share following the company's IPO.

Kirk G. Nielsen, a director of SpyGlass Pharma, Inc., filed an amended Form 4 to correct reported beneficial ownership following preferred stock conversion.

SpyGlass Pharma Director and 10% owner Ali Behbahani reported significant acquisitions of common stock, including a direct purchase and conversions of preferred shares, following the company's IPO.

A director and 10% owner of SpyGlass Pharma, Scott D. Sandell, reported the automatic conversion of preferred stock into common stock and a significant common stock purchase coinciding with the company's initial public offering.

Director and 10% owner Carmen Chang reported significant acquisitions of SpyGlass Pharma common stock, primarily through preferred stock conversions and a direct purchase, coinciding with the company's IPO.

SpyGlass Pharma director Paul Edward Walker reported significant conversions of preferred stock to common stock and a direct purchase, increasing his indirect beneficial ownership ahead of the company's IPO.

Edward T. Mathers, a director and 10% owner of SpyGlass Pharma, Inc., significantly increased his indirect beneficial ownership to over 6 million common shares through conversions and a direct purchase.

SpyGlass Pharma Director Geoffrey B. Pardo increased his indirect beneficial ownership of common stock through a preferred stock conversion and a direct purchase ahead of the company's IPO.

SpyGlass Pharma Director Bilal Arshad Khan acquired 135,000 shares of common stock at $16 per share, increasing his direct and indirect holdings.

SpyGlass Pharma Director Kirk Nielsen increased his indirect beneficial ownership of common stock through conversions and a direct purchase ahead of the company's initial public offering.

Vensana Capital, a 10% owner and director, converted preferred stock to common shares and purchased additional common stock in SpyGlass Pharma, Inc. prior to its IPO.

Dr. Zachary Scheiner, a director representing RA Capital Management at SpyGlass Pharma, was granted 27,400 stock options at an exercise price of $16, vesting monthly over three years.

SpyGlass Pharma Director and 10% owner Ali Behbahani was granted 27,400 stock options with a $16 exercise price, vesting monthly over three years.

Kirk G. Nielsen, a Director and 10% owner of SpyGlass Pharma, Inc., was granted 27,400 stock options with a $16 exercise price.

SpyGlass Pharma Director Zachary Scheiner was granted 27,400 stock options with a $16 exercise price, vesting monthly over three years.

SpyGlass Pharma, Inc. Director Bilal Arshad Khan was granted 13,700 stock options with an exercise price of $16, vesting over one year or until the next annual meeting.

SpyGlass Pharma, Inc. director Habib J. Dable was granted 27,400 stock options with an exercise price of $16, vesting monthly over three years.

SpyGlass Pharma Director Geoffrey B. Pardo was granted 27,400 stock options with an exercise price of $16, vesting monthly over three years.

SpyGlass Pharma, Inc. Director Michael Dybbs was granted 27,400 stock options with an exercise price of $16, vesting monthly over three years.

SpyGlass Pharma, Inc. Director Elizabeth G. O'Farrell was granted 13,700 stock options with an exercise price of $16, vesting over one year or until the next annual meeting.

SpyGlass Pharma, Inc.'s Chief Operating Officer, James Robert Dennewill Jr., was granted 105,000 stock options with an exercise price of $16.

SpyGlass Pharma's Chief R&D Officer, Chetan Pratap Pujara, acquired 105,000 stock options at an exercise price of $16, signaling management's long-term commitment.

SpyGlass Pharma, Inc. has granted 105,000 stock options to Malik Y. Kahook, its President, Chief Medical Officer, and Executive Chair, with a vesting schedule over four years.

SpyGlass Pharma's Chief Financial Officer, Jean-Frederic Viret, was granted 17,500 stock options with a $16 exercise price, vesting over four years.

SpyGlass Pharma's CEO, Patrick H. Mooney, was granted 300,000 stock options with an exercise price of $16, vesting over four years.